Tenax Therapeutics, Inc. announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). PH-HFpEF is a common condition with a poor outcome (5 year survival less than 50%). Given that no therapies are approved to treat an estimated 1.5 million patients who suffer from this condition, it represents a disease with high unmet medical need. Tenax plans to initiate a Phase 2 trial in PH-HFpEF patients in the early part of the third quarter of 2018. Based on strong feedback from multiple experts in the field of PH-HFpEF, Tenax believes that PH-HFpEF represents a very attractive area for Levosimendan clinical development. Several compelling reasons to pursue development in pulmonary hypertension include: Positive Levosimendan Data -Preliminary studies of favorable drug effects in patients with pulmonary hypertension; High Unmet Need -No drugs are approved for the treatment of PH-HFpEF; Large Population -Estimated US Prevalence PH-HFpEF exceeds 1.5 million patients; High Value Chronic Therapy -Unique long-lasting drug effects allow for chronic intermittent therapy; and Efficient Clinical Development Plan - A single Phase 2 trial designed to establish the benefits of levosimendan in PH-HFpEF patients. A group of globally recognized pulmonary hypertension and HFpEF experts have helped advise Tenax on this new development opportunity.